Acute Myelogenous Leukemia
Research results from St. Jude Children's Research Hospital, Department of Pharmaceutical Sciences update understanding of acute myelogenous leukemia
Published in Cancer Weekly, July 1st, 2008
Researchers detail in 'Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia,' new data in acute myelogenous leukemia. According to a study from the United States, "We compared the antitumor activities of the multitargeted tyrosine kinase inhibitors imatinib, sorafenib, and sunitinib to determine which inhibitor is best suited to be used for the treatment of acute myelogenous leukemia (AML). In nine human AML cell lines, sorafenib and sunitinib were more potent inhibitors of cellular proliferation than imatinib (IC50 , 0.27 to >40, 0.002-9.1, and 0.007-13 micromol/L for imatinib, sorafenib, and sunitinib,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-07-01)
More Articles from Cancer Weekly
- JAMA and Archives Journals
Radiation treatment for cancer after radical prostatectomy linked with increased survival - Addiction Medicine
"Magic Meadow Therapy - Guidance to Happiness" Now Available in English! - Cancer Gene Therapy
Data on cancer gene therapy described by researchers at Thomas Jefferson University - Cancer Gene Therapy
Data on cancer gene therapy discussed by P. Gao and colleagues - Cancer Gene Therapy
New cancer gene therapy data have been reported by researchers at University of Utrecht - Cancer Gene Therapy
New cancer gene therapy research has been reported by scientists at University of California - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
